[CLSTR]
< Back to situations

[ORGANIZATION]

New England Journal of Medicine

Featured in 42 tracked stories · first seen

Situations

[ACTIVE] [HEALTH] [US] [BR] [GB]

GLP-1 drugs: clinical trends, safety, and market shifts

291 clusters · 1104 sources · last updated

Latest: Novo Nordisk faces lawsuits over Ozempic and NAION risks

Since mid-2026, the expansion of GLP-1 agents for obesity has been accompanied by intensified safety monitoring and evolving clinical data. Research suggests secondary benefits, including a 21% lower risk of fragility fr

[ACTIVE] [HEALTH] [BR] [CH] [DE]

Advancements in vision restoration and ophthalmology

2 clusters · 16 sources · last updated

Latest: Optogenetic therapy restores rudimentary vision in clinical trial

Developments in ophthalmology are progressing through both assistive technology and advanced clinical research aimed at visual rehabilitation. Initial reports highlight the mapping of specialized rehabilitation centers i

[ACTIVE] [HEALTH] [DE] [ES] [MX]

Biological and social impacts of seasonal transitions

12 clusters · 70 sources · last updated

Latest: Seasonal changes impact metabolism and respiratory health

Health experts continue to address the physiological and psychological challenges associated with seasonal transitions. As the season shifts toward autumn, the transition can trigger ‘autumn fatigue’ or seasonal asthenia

[ACTIVE] [HEALTH] [US] [DE] [IT]

Clinical applications and access of CAR-T cell therapy

16 clusters · 59 sources · last updated

Latest: Oncology researchers expand immunotherapy research for CLL and HIV-associated lymphoma

CAR-T cell therapy continues to expand its clinical utility across oncology and autoimmune diseases. In oncology, the therapy is transforming treatment for aggressive lymphomas and resistant blood cancers. A significant

[ACTIVE] [HEALTH] [AU] [US] [GB]

STAREE trial and evolving cholesterol treatments

9 clusters · 20 sources · last updated

Latest: STAREE study: Atorvastatin reduces major heart events in elderly by 30%

The STAREE trial, a large-scale clinical study involving nearly 10,000 participants from Australian general practices, has demonstrated that daily atorvastatin significantly reduces the risk of major cardiovascular event

[QUIET] [HEALTH] [KR] [SE]

Atrial fibrillation stroke prevention and cognitive research

5 clusters · 10 sources · last updated

Latest: Oral anticoagulants studied for intermediate stroke risk in atrial fibrillation

Clinical research has increasingly supported the use of oral anticoagulants (OAC) for stroke prevention in patients with atrial fibrillation (AF) at intermediate risk. Data from the SINGLE-AF trial, published in The New

[QUIET] [HEALTH] [KR]

Severance Cardiovascular Hospital cardiology advancements

2 clusters · 6 sources · last updated

Latest: Severance Cardiovascular Hospital reaches 10,000 atrial fibrillation procedures

Severance Cardiovascular Hospital has demonstrated significant advancements in cardiology through both academic research and clinical practice. Between November 2023 and August 2024, the hospital’s Department of Cardiolo

[QUIET] [HEALTH] [US] [AR] [GR]

FDA approves Rasonque for pancreatic cancer; access disputes

40 clusters · 304 sources · last updated

Latest: Angelica Pasculli seeks access to US cancer drug unavailable in Europe

On 26 August 2026, the U.S. Food and Drug Administration (FDA) granted expedited approval to daraxonrasib, marketed as Rasonque, for treating adults with metastatic pancreatic ductal adenocarcinoma (PDAC). Developed by R

[QUIET] [HEALTH] [US] [VN] [BR]

Global health risks and complications of RSV

7 clusters · 19 sources · last updated

Latest: RSV vaccines reduce elderly hospitalization and death risk by over 80%

Respiratory Syncytial Virus (RSV) continues to pose a significant global health threat, particularly to infants and the elderly. Medical experts highlight that the virus causes millions of infant hospitalizations annuall

[QUIET] [HEALTH] [IT]

Eplontersen trials and Italian healthcare advancements

2 clusters · 90 sources · last updated

Latest: Italy advances healthcare through infrastructure and medical innovation

Clinical developments regarding the drug eplontersen have shown divergent results depending on the specific condition being treated. In the phase 3 CARDIO-TTRansform trial, eplontersen failed to significantly reduce card

[QUIET] [HEALTH] [CN] [ES] [JP]

Hepatitis B treatment and clinical developments

2 clusters · 7 sources · last updated

Latest: Hepatitis B treatment shifts focus to viral load to prevent liver cancer

Developments in chronic hepatitis B management have focused on both new therapeutic options and updated clinical guidelines. Clinical trials for the drug bepirovirsen, developed by GSK and Ionis Pharmaceuticals, demonstr

[QUIET] [HEALTH] [US] [AU] [CN]

CRISPR gene-editing therapy for cholesterol reduction

4 clusters · 16 sources · last updated

Latest: CRISPR gene-editing therapy reduces LDL cholesterol by over 50% in single dose

Researchers have reported successful results from clinical trials involving CRISPR-Cas9 gene-editing therapy designed to reduce cholesterol levels. Initial pilot study data involving 15 patients indicated that a single

[QUIET] [HEALTH] [BA] [HR] [LV]

Hypertension management through lifestyle and diet

6 clusters · 33 sources · last updated

Latest: Blood pressure fluctuations and dietary management

Medical guidance for managing hypertension emphasizes lifestyle modifications and dietary adjustments to mitigate cardiovascular and renal risks. Experts highlight the DASH diet—prioritizing fruits, vegetables, whole gra

[QUIET] [HEALTH] [DK] [ES] [IN]

REACT study on silent atherosclerosis prevalence

3 clusters · 27 sources · last updated

Latest: Atherosclerosis prevalence found high in young adults in new study

The REACT international research study, involving participants from Spain and Denmark, has revealed that silent atherosclerosis is significantly more prevalent among healthy, asymptomatic adults than previously estimated

[QUIET] [HEALTH] [US] [ES] [IT]

AstraZeneca tozorakimab COPD clinical trials

2 clusters · 17 sources · last updated

Latest: AstraZeneca drug tozorakimab reduces COPD exacerbations by 30%

AstraZeneca has reported positive results from two Phase 3 clinical trials, OBERON and TITANIA, regarding its experimental monoclonal antibody, tozorakimab, for the treatment of chronic obstructive pulmonary disease (COP

[QUIET] [HEALTH] [CN] [US]

Discovery of ALTNV tick-borne virus in China

3 clusters · 20 sources · last updated

Latest: China discovery of ALTNV tick-borne virus raises global health concerns

Researchers from Beijing’s State Key Laboratory of Pathogen and Biosecurity have identified a new tick-borne virus named the Asian longhorned tick nairovirus (ALTNV), belonging to the orthonairovirus group. The discovery

Also covered in